Welcome to our dedicated page for IN8bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on IN8bio stock.
IN8bio, Inc. (Nasdaq: INAB) is a clinical-stage biotechnology company pioneering the development of novel therapies aimed at treating various cancers. Using allogeneic, autologous, and genetically modified gamma-delta T cells, IN8bio is revolutionizing cancer treatment. The company’s mission is to create groundbreaking therapies that harness the power of the body’s immune system to target and destroy cancer cells.
IN8bio's robust portfolio includes several promising product candidates:
- INB-400: Aimed at treating newly diagnosed glioblastoma (GBM), this product is currently in a Phase 2 clinical trial.
- INB-100: Designed for patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, this therapy is under Phase 1 clinical trials.
- INB-200: Another promising candidate targeting GBM, it has shown encouraging preliminary clinical data at the 2024 ASCO Annual Meeting.
- Additional products, like INB-300 and INB-500, are in various stages of development targeting both solid and liquid tumors.
Recently, IN8bio disclosed significant advancements in the treatment of GBM, utilizing their innovative gamma-delta T cell-based adoptive cellular therapy. A peer-reviewed publication highlighted the strategy and future direction of their novel treatment methods.
Financially, IN8bio extends its cash runway into 2025, bolstered by additional capital from a private placement in December 2023. The company continues to pursue more funding to advance its clinical trials and achieve its milestones.
IN8bio's groundbreaking work has garnered attention in the biotech field, especially for its genetically modified gamma-delta T cells, which are the first to be advanced into clinical trials. The company’s approach shows great potential in improving progression-free survival (PFS) and overall survival (OS) rates for GBM and other cancers.
For investors and stakeholders, IN8bio provides exciting opportunities as it moves towards commercializing its therapies, aiming to address significant unmet medical needs in oncology. For more information, please visit IN8bio.
IN8bio, Inc. has appointed Trishna Goswami, M.D. as Chief Medical Officer, effective immediately. Dr. Goswami brings over a decade of experience in immuno-oncology drug development, having worked with notable companies such as Gilead and AstraZeneca. Her expertise includes clinical development for both solid and hematologic tumors, making her a significant addition to IN8bio's leadership team. The company focuses on advancing gamma-delta T cell therapies using its DeltEx platform to improve cancer treatment outcomes. This appointment aligns with IN8bio's goal of progressing multiple therapeutic candidates through clinical development.
IN8bio (Nasdaq: INAB) announced a poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 13, 2021. Dr. Kate Rochlin will present preclinical data on the potential of DeltEx drug-resistant immunotherapy gamma-delta T cells combined with PARP inhibitors to enhance tumor immunogenicity. Notably, temozolomide and niraparib resulted in up to a 29-fold increase in NKG2DL expression in resistant glioblastoma cell lines. This indicates the potential of orthogonal therapies to improve clinical efficacy against solid tumors.
IN8bio, Inc. (Nasdaq: INAB) raised $32.3 million in net proceeds from its IPO, enhancing its capital for clinical programs. The company completed patient dosing of INB-100 in a Phase 1 trial for leukemia while also publishing preclinical data on INB-200 in Scientific Reports. Financial results for Q3 2021 show a cash position of $40.7 million, with R&D expenses rising to $1.4 million. Net loss for the quarter was $3.4 million, compared to $1.7 million in Q3 2020. IN8bio continues to expect initial trial results in 2022 and topline results for all cohorts in 2023.
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company, announced its participation in three scientific conferences this November. Presentations will cover gammas-delta T-cell therapies aimed at treating various cancers. Key events include the Protein & Antibody Engineering Summit on November 4, the SITC Annual Meeting on November 13, and the Society for Neuro-Oncology meeting on November 19. Presenters include top executives and scientists from IN8bio, showcasing innovative cancer treatment approaches using the DeltEx platform.
IN8bio announced significant survival benefits from concurrent dosing of MGMT-modified gamma-delta T cells with Temozolomide (TMZ) in high-grade glioma models. The findings, published in Scientific Reports, support the clinical development of the company’s Drug Resistant Immunotherapy (DRI) technology. Currently, a Phase 1 trial is evaluating DRI with TMZ in glioblastoma multiforme at the University of Alabama at Birmingham. This approach aims to enhance tumor response while maintaining immune functionality.
IN8bio, a clinical-stage biopharmaceutical company, announced that CEO William Ho will present at BioFuture 2021 on October 5 at 10:30 a.m. EDT and participate in a panel on oncology at 1:30 p.m. EDT. Additionally, Kate Rochlin, VP of Operations, will present on gamma-delta T-cell programs at the Advanced Therapies Congress & Expo 2021 the same day at 11:30 a.m. EDT. IN8bio focuses on innovative therapies for tumors using its DeltEx platform, with two Phase 1 trials ongoing for gamma-delta T-cell products targeting glioblastoma and leukemia.
IN8bio, Inc. announced operational and financial highlights for Q2 2021, reporting significant progress in its Phase 1 clinical trials for INB-200 and INB-100. The successful completion of the first cohort treatment in both trials demonstrates strong potential in solid tumors and leukemia. Following a $40M IPO in August 2021, the company bolstered its cash position to $32.6M. However, IN8bio recorded a net loss of $3.1M for the quarter, with R&D expenses rising to $2.1M, indicating ongoing investment in its clinical programs.
IN8bio, a clinical-stage biopharmaceutical company, announced that CEO William Ho will present at two virtual events: NewYorkBIO Virtual Breakfast Series on August 31 at 9 am EDT, and H.C. Wainwright’s 23rd Annual Global Investment Conference from September 13-14. The presentations will highlight the company's innovative gamma-delta T-cell therapies using its DeltEx platform. The H.C. Wainwright presentation will be available for 90 days post-release. IN8bio is currently conducting Phase 1 clinical trials for its lead product candidates targeting glioblastoma and leukemia.
IN8bio has completed dosing for the first cohort in a Phase 1 clinical trial of INB-100, a gamma-delta T-cell therapy for leukemia patients undergoing haploidentical stem cell transplant. No severe adverse infusion reactions or dose limiting toxicities were reported among the three patients. The first two patients remain in complete remission over one year post-dosing. The trial aims to evaluate safety, tolerability, and overall survival, with topline data expected in 2023. IN8bio focuses on innovative T-cell therapies to improve treatment outcomes for leukemia and other cancers.
IN8bio (Nasdaq: INAB) has appointed Emily Fairbairn and Luba Greenwood to its Board of Directors. Both appointees bring extensive experience in the biopharmaceutical and life sciences sectors. Fairbairn, an influential investor and former CEO of Ascend Capital, focuses on corporate governance, while Greenwood's background includes leadership roles at Google Life Sciences and Roche. Their terms will end at the 2022 annual stockholders' meeting. IN8bio aims to advance its clinical-stage gamma-delta T-cell therapies for cancer treatment, utilizing its innovative DeltEx platform.
FAQ
What is the current stock price of IN8bio (INAB)?
What is the market cap of IN8bio (INAB)?
What does IN8bio, Inc. do?
What are the main products of IN8bio?
What recent advancements has IN8bio made?
How is IN8bio funded?
What is the significance of IN8bio's gamma-delta T cells?
How can I learn more about IN8bio’s clinical trials?
What is INB-400?
Where is IN8bio headquartered?
Who can I contact for investor relations?
How does IN8bio contribute to cancer research?
